Pilot study offers oral drug to bridge care gap for underserved leukemia patients
NCT ID NCT06370000
Summary
This study is testing whether an oral maintenance drug (azacitidine) is a feasible and tolerable option to help prevent cancer relapse in patients with acute myeloid leukemia (AML) who are in remission. It focuses on patients who are medically eligible for a stem cell transplant but face significant social or economic barriers that prevent them from getting one. The main goal is to see if patients can complete at least four cycles of this oral therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.